Paclitaxel and Carboplatin as Second-Line Therapy in Women with Platinum-Sensitive Ovarian Carcinoma Treated with Platinum and Paclitaxel as First-Line Therapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 1, 2004, Pages 46-50

  Eltabbakh, Gamal H ^a,b   Yildirim, Zafer ^a   Adamowicz, Renate ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b Lake Champlain Gynecologic Oncology   (United States)

Author keywords

Carboplatin; Ovarian cancer; Paclitaxel; Second line chemotherapy

Indexed keywords

CARBOPLATIN; PACLITAXEL; PLATINUM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; NEUTROPENIA; OVARY CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME;

EID: 0842348920     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000046120.23169.18     Document Type: Article

References (38)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics. CA Cancer J Clin 2001;51:15-36.
2. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
3. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
4. Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18:3084-92.
5. Ozols RF, Bundy BN, Fowler J, et al. Randomized phase III study of cisplatin/paclitaxel in optimal stage III epithelial ovarian cancer (a Gynecologic Oncology Group trial (GOG 158). Proc Am Soc Clin Oncol 1999;18:356a.
6. DuBois A, Neijt JP, Thigpen JT, et al. First-line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer: a new standard of care? Ann Oncol 1999;10:S35-41.
7. Gore ME, Fryatt I, Wiltshaw E, et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990;36:207-11.
8. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-93.
9. Seltzer V, Vogl S, Kaplan B, et al. Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent. Gynecol Oncol 1985;21:167-76.
10. Lorenz E, Hagen B, Himmelmann A, et al. A phase II study of biweekly administration of paclitaxel in patients with recurrent epithelial ovarian cancer. Int J Gynecol Cancer 1999;9:373-6.
11. Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994;12:1748-53.
12. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-9.
13. Menzin AW, Aikins JK, Wheeler, et al. Surgically documented responses to paclitaxel and cisplatin in patients with primary peritoneal carcinoma. Gynecol Oncol 1996;62:55-8.
14. Ransom DT, Patel SR, Keeney GL, et al. A review of 33 cases treated with platin-based chemotherapy. Cancer 1990;66:1091-4.
15. Barakat RR, Rubin SC, Saigo PE, et al. Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube. Gynecol Oncol 1991;42:156-60.
16. Gemignani M, Hensley ML, Cohen R, et al. Paclitaxel-based chemotherapy in carcinoma of the fallopian tube. Gynecol Oncol 2001;80:16-20.
17. Cormio G, Maneo A, Gabriele A, et al. Treatment of fallopian tube carcinoma with cyclophosphamide, adriamycin, and cisplatin. Am J Clin Oncol 1997;20:143-5.
18. Trope C, Hogberg T, Kaern J, et al. Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience. Ann Oncol 1998;9:1301-7.
19. Abu-Rustum NR, Aghajanian C, Barakat RR, et al. Salvage weekly paclitaxel in recurrent ovarian cancer. Semin Oncol 1997;24:S15-67.
20. Cantu MG, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 2002;20:1232-7.
21. Bolis G, Scarfone G, Giardina G, et al. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol 2001;81:3-9.
22. Goldberg JM, Piver MS, Hempling RE, et al. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer. Gynecol Oncol 1996;63:312-7.
23. Gronlund B, Hogdall C, Hansen HH, et al. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol 2001;83:128-34.
24. Rose PG, Fusco N, Fluellen L, et al. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 1998;16:1494-7.
25. Dizon DS, Hensley ML, Poynor EA, et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 2002;20:1238-47.
26. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997;8:963-8.
27. McGuire WP, Blessing JA, Bookman MA, et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2000;18:1062-7.
28. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22.
29. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998;16:405-10.
30. Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994;86:1530-3.
31. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997;15:987-93.
32. Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998;16:3345-52.
33. Katsumata N, Tsunematsu R, Tanaka K, et al. A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study. Ann Oncol 2000;11:1531-6.
34. Burger RA, DiSaia PJ, Roberts JA, et al. A phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol 1999;72:148-53.
35. Culine S, Mayeur D, Mayer F, et al. Topotecan and paclitaxel as second-line treatment of advanced ovarian cancer (AOC) A GINECC phase II trial. Proc Am Soc Clin Oncol 2001;20:215a.
36. Bolis G, Scarfone G, Sciatta C, et al. A phase I/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol 2001;83:477-80.
37. du Bois A, Luck HJ, Pfisterer J, et al. Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer. A dose finding study by the Arbeitsgemeinschaft Gynakologische Oncologie (AGO) Ovarian Cancer Study Group. Ann Oncol 2001;12:1115-20.
38. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000;18:106-15.